The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 8.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (1 analysts) rates it none, with a mean price target of $1.
Baladna Q.P.S.C.
BLDN.QA · DOH · QAR · Market cap $3.2B
Baladna Q.P.S.C., together with its subsidiaries, manufactures and sells dairy products in Qatar.
FAIL · Does not pass the screenPrice as of 12 Nov 2026Daily close, not a live quoteLast reviewed 4 days ago
Screened 2026-11-12 · the tape above runs as of 04:19 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price1.32 QAR at the 12 Nov 2026 close
- Fair value1.36. Our model only; only one analyst covers it, too few to cross-check it.
- Our value readFair vs our fair value, as of 12 Nov 2026
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenDoes not pass
- Last reviewed12 Nov 2026 (4 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: 1.26 QAR to 1.64 QAR, base estimate 1.36 QAR (screen dated 2026-11-12).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Baladna Q.P.S.C. holds its Markup at $1.32. Consolidating, no directional conviction, held for 6 days.
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 6 days |
| Price at the screen | $1.32 |
| Valuation | 4.63 trailing · 10.95 forward price to earnings |
| Values screen | FAIL |
| Beta | 0.37 |
Five Screens, Shown in Full
Does not pass. Debt ratio
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 41.84% | Below 33% | Interest-bearing debt is 41.8% of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 8.30% | Below 49% | Money owed to the company is 8.3% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Baladna Q.P.S.C.'s business is in a permissible area, but its interest-bearing debt is about 42% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-14. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when BLDN.QA's ethical verdict changes
Today BLDN.QA does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our model only; only one analyst covers it, too few to cross-check it.
Our analysis reads Fair vs our fair value, as of 12 Nov 2026: it trades at roughly a 3% discount to our 1.36 QAR fair value, moderate competitive moat, 5.60% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in QAR, drawn from the 2026-11-12 screen. The gold marker is the market price at the same screen. A 2.9% discount to the base estimate.
Reading the gap · Both our model and the analysts see meaningful upside from here.
ProjectionsWhere our models see it going: fair-value estimate 1.36 QAR, with a range of 1.26 QAR to 1.64 QAR, dated to the 2026-11-12 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsWhy it is worth knowing
A quality business: a moderate moat and 45% profit margins. It trades close to our 1.36 QAR fair value, so the easy discount is gone; you would be paying up for the quality.
| Forward P/E | 11.0xpriced for continued growth |
| Trailing P/E | 4.6xvery cheap relative to earnings |
| EPS, trailing | 0.26 |
| EPS, forward | 0.11 |
| Revenue growth | +5.6%slow but positive growth |
| Profit margin | 44.6%highly profitable on every dollar of sales |
| Return on equity | 17.3%a solid return on shareholder capital |
| FCF yield | -4.42% |
| Debt to equity | 0.79moderate, manageable leverage |
| Current ratio | 1.52healthy short-term liquidity |
| Beta | 0.37barely tracks the market's swings |
| 52-week range | 1.16 - 1.55 |
| Moat | MODERATE |
| Market cap | $3.2B |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: its business and earnings are exposed to Qatar and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeBLDN.QA trades on DOH (the company is based in Qatar). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 2.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (1 analysts) rates it none, with a mean price target of $1.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (1 analysts) rates it none, with a mean price target of $1.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 4.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (1 analysts) rates it none, with a mean price target of $1.
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (1 analysts) rates it none, with a mean price target of $1.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (1 analysts) rates it none, with a mean price target of $1.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.2% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (1 analysts) rates it none, with a mean price target of $1.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (1 analysts) rates it none, with a mean price target of $1.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Qatari group develops $3.3 billion agricultural project in Syria Yahoo Finance · 3 Aug 2026
- Baladna works with World Bank financing arm in Syria dairy project Just Food · 27 Apr 2026
- Baladna works with World Bank financing arm in Syria dairy project Yahoo Finance · 27 Apr 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $1.34 | -3.3% | · | $967 | -3.3% |
| 2 months | $1.26 | +2.5% | · | $1,025 | +2.5% |
| 3 months | $1.19 | +8.4% | · | $1,084 | +8.4% |
| 6 months | $1.36 | -5.3% | · | $947 | -5.3% |
| 1 year | $1.17 | +10.7% | · | $1,107 | +10.7% |
| 2 years | $1.16 | +11.2% | · | $1,112 | +11.2% |
| 3 years | $1.25 | +3.0% | $0.06 | $1,079 | +7.9% |
| 5 years | $1.30 | -0.4% | $0.11 | $1,080 | +8.0% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever BLDN.QA does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.